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Abstract
Cough is one of the most common symptoms for which patients seek medical attention from primary care
physicians and pulmonologists. Cough is an important defensive reflex that enhances the clearance of secretions
and particles from the airways and protects the lower airways from the aspiration of foreign materials. Therapeutic
suppression of cough may be either disease-specific or symptom related. The potential benefits of an early
treatment of cough could include the prevention of the vicious cycle of cough. There has been a long tradition in
acute cough, which is frequently due to upper respiratory tract infections, to use symptom-related anti-tussives.
Suppression of cough (during chronic cough) may be achieved by disease-specific therapies, but in many patients
it is often necessary to use symptomatic anti-tussives, too. According to the current guidelines of the American
College of Chest Physician on “Cough Suppressants and Pharmacologic Protussive Therapy” and additional clinical
trials on the most frequent anti-tussive drugs, it should be possible to diagnose and treat cough successfully in a
majority of cases. Among drugs used for the symptomatic treatment of cough, peripherally acting anti-tussives
such as levodropropizine and moguisteine show the highest level of benefit and should be recommended
especially in children. By improving our understanding of the specific effects of these anti-tussive agents, the
therapeutic use of these drugs may be refined. The present review provides a summary of the most clinically
relevant anti-tussive drugs in addition to their potential mechanism of action.
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Introduction
In addition to being an airway defence mechanism,
coughing is a very common symptom observed in many
diseases other than those affecting the respiratory sys-
tem. To recognize its cause is not always an easy task.
Where possible, the clinician should avoid treatment
based on symptoms only which often only serves the
purpose to reassure the patient or the parents (in the
case of a paediatric patient). On the other hand it is
worth mentioning that internal medicine physicians are
frequently overwhelmed by requests for help by patients
who report coughing, alone or together with other non-
specific symptoms such as malaise, pharyngodynia, and
a mild temperature. In such cases, treatment of symp-
toms alone appears justified as a therapeutic approach.
However, it must be emphasized that a high level of sus-
picion needs to be maintained, especially when coughing
persists which would require a thorough investigation of
other possible causes.
This review summarises the effectiveness of sympto-
matic cough remedies including two specific drugs
(levodropropizine and moguisteine) which have been
tested in the symptomatic treatment of cough, and have
received Grade A evidence in the treatment of cough
due to either acute or chronic bronchitis. In addition we
identify missing pieces of evidence regarding the efficacy
of symptomatic cough treatments as well as associated
side effects. Moreover, clear treatment algorhythms still
need to be established for acute and chronic cough
Methods
A thorough systematic literature search was conducted
in the main international search databases (Pubmed,
Embase, Biosis) of all articles (both original clinical trials
and reviews) published in the period from 1950 up to
now. For this search, all keywords related to cough
(acute, sub acute and chronic), cough mechanism and
pathogenesis, cough treatment (cough suppressants,
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were used.
Authors’ recommendations were based on this clinical
evidence and on available guidelines for clinical practice
Definition and causes of acute, sub acute and chronic
cough
Acute cough is rather arbitrarily referred to as a cough
lasting for a maximum of 3 weeks. In the majority of
patients, it is caused by upper respiratory tract infections
(URTI), acute bronchitis or tracheo-bronchitis due to
bacterial or more frequently viral infections [1]. It has
been estimated that only few patients with URTI-
induced cough seek medical attention. Acute cough due
to such infections is usually self-limited and subsides
within one to two weeks along with the clearing of the
infection.
There are no targets or reliable measures to predict
the duration of a cough at its onset (i.e., resolution
within 3 weeks). Neither is it possible to predict which
cough will persist into the sub acute or chronic stage.
The issue is further complicated by the fact that effec-
tive therapy can abort or abbreviate the duration of a
cough, whereas failure to institute effective therapy can
convert what might have been an acute cough into a
sub acute or chronic one. Furthermore, recurrent acute
episodes of cough can be a manifestation of an undiag-
nosed chronic disease (e.g., asthma). Nevertheless, keep-
ing these caveats in mind, a relatively ‘’standard’’
diagnostic and therapeutic approach based on the dura-
tion of the cough has proved useful [2-4].
Sub acute cough has been defined as a cough lasting
for 3-8 weeks. Following specific infections (e.g., M.
pneumoniae), an increase in bronchial hyper-responsive-
ness may persist, which can cause or maintain sub acute
cough that can remain bothersome for a period of
weeks even after the inciting infection has completely
resolved. Post-infectious airway hyperresponsiveness
resulting in a sub acute cough has been scarcely studied.
Randomised, controlled trials to prevent and/or treat
this condition are missing. Although inhaled corticoster-
oids or leukotriene receptor antagonists are frequently
prescribed for this condition, there is no controlled
scientific evidence to support their use, which is self-
limited in many cases. Further causes of sub acute
cough include B. pertussis, where coughing persists with
disabling paroxysms, despite resolution of the infection.
While the rate of persons vaccinated decreases, pertus-
sis-induced cough becomes more frequent in several
countries [5]. Recent pertussis infection should be ruled
out in children and adults with sub acute cough irre-
spective of any prior vaccination. Cough as a result of a
B. pertussis infection usually leads to paroxysmal epi-
sodes of coughing with a characteristic inspiratory
whoop, especially in children. However, this can be
absent, especially in adults. Non-infectious causes of sub
acute cough include gastroesophageal reflux, aspiration
and bronchial asthma, which is a likely diagnosis when
cutaneous sensitisations to seasonal allergens can be
shown in an allergen skin test or if symptoms occur fol-
lowing exposure to environmental allergens or pollu-
tants. Subclinical congestive heart failure can be a cause
of acute and sub acute cough, especially during periods
of fluid overload. Rare cases of sub acute cough include
pulmonary sequestration, and very occasionally Tour-
ette’s syndrome, which can manifest itself solely as par-
oxysmal coughing episodes
Differential diagnosis of acute and sub acute cough
The differential diagnosis of acute and sub acute cough
is wide ranging and includes a plethora of diseases.
Chronic cough is most frequently related to the chronic
inhalation of cigarette smoke by either active or passive
smoking [6]. The diagnostic challenge for clinician faced
with acute or sub-acute chough is the identification of
benign, self-limited episodes of mostly infection asso-
ciated cough versus severe, potentially life-threatening
diseases as the underlying cause of the presenting
cough. Exposure to particulate matter has also been
identified as a source of cough [7]. However, most cases
of acute and sub acute cough are caused by broncho-
pulmonary infections from various organisms [8]. There
is little doubt that environmental and infectious
mechanisms can synergistically contribute to the patho-
genesis as well as the severity and duration of the cough
but this has not been fully evaluated. The major chal-
lenge for the clinician still remains to be the early iden-
tification of severe underlying diseases, such as
bronchial carcinoma or tuberculosis in patients with
cough of recent onset that does not yet fulfil the criteria
of a chronic cough. The general approach to the treat-
ment of a patient with any cough begins with a search
for the cause of any acute and/or sub acute cough (Fig-
ure 1 and 2). This involves differentiation into relatively
benign but also potentially life-threatening causes. A
detailed history is key to the identification of the under-
lying cause and any subsequent decision if treatment for
cough or its underlying condition is necessary. The
onset of cough can provide initial clues as to its origin.
Abrupt onset can be related to aspiration, especially in
small children and elderly persons. Signs and symptoms
of an upper respiratory tract infection point to the most
common and usually benign reasons for acute or sub
acute cough. However, they can precede severe pneumo-
nia and therefore occasionally require close observation.
A history or signs and symptoms of gastroesophageal
reflux can be associated with intermittent cough. A
detailed history of recent medication can reveal ACE-
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Page 2 of 12Figure 2 Sub acute cough algorithm for the management of patients aged > 15 years with cough lasting 3 to 8 weeks. See the legend
of Figure 1 for other section references. Taken from Ref [61] with permission from the publisher.
Figure 1 The acute cough algorithm for the management of patients aged ≥15 years with cough lasting < 3 weeks. PE = pulmonary
embolism; Dx = diagnosis; Rx = treatment; URTI = upper respiratory tract infection; LRTI = lower-respiratory tract infection. Taken from Ref [61]
with permission from the publisher.
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usually occurs within the first few days after initiation of
treatment, but can occur even after prolonged periods of
previous therapy. A detailed smoking history including the
number of pack years as well as the age of onset of smok-
ing is mandatory in the workup of any cough. Exposures
at the workplace to noxious and/or sensitising agents are
often overlooked as a cause of cough or an occupational
asthma presenting as cough. Troublesome nocturnal
coughing episodes which may include vomiting should
prompt investigation into recently acquired pertussis, gas-
troesophageal reflux and more frequently asthma, espe-
cially in children. In addition, in many patients, especially
young children, cough is often the first and only symptom
of asthma. A detailed history into potentially aggravating
factors as well as the nature of the cough, namely produc-
tive or non-productive forms of sputum may be helpful.
The clinical examination of a patient with cough
includes the nose, for obstruction and/or discharge as well
as the oropharynx which should be closely inspected for
direct or indirect signs of postnasal drip or other abnorm-
alities. The ear, innervated by the vagal nerve, can also be
a cause of cough. Therefore, the external acoustic meatus
should also be examined to exclude cerumen or other for-
eign bodies. A detailed examination of the chest, including
the heart, is mandatory but goes beyond the scope of this
article. According to most guidelines, a chest radiograph
in the anterior and lateral view is warranted in any unex-
plained cough that persists for more than 2 weeks.
In the case of sputum production, this should be ana-
lysed for the approximate quantity and colour, which
can suggest bacterial growth. However, in most cases of
uncomplicated URTI, sputum bacteriology is not needed
and should be reserved for severe or complicated cases
such as in the setting of immune-suppression or co-
morbid lung disease warranting antibiotic therapy. Spu-
tum cytology is an underused diagnostic tool which
should be employed in any patient with a smoking his-
tory and an unexplained cough. The diagnosis of psy-
chogenic cough, although probably not uncommon,
needs to remain a diagnosis of exclusion.
With cough being one of the most frequent symptoms
of patients seeking medical advice from general practi-
tioners and specialists, the difficult task of physicians
caring for patients with cough is to identify severe
causes such as neoplastic disease, severe infections (e.g.,
tuberculosis, etc.) and inflammatory conditions (e.g.,
Wegener’s granulomatosis, etc.) without subjecting every
patient with benign, self-limiting cough to extensive
diagnostic procedures.
Chronic and persisten cough
In 1977, R. S. Irwin reviewed the most common causes
of persistent and chronic cough [10]. In that paper, he
postulated that due to the fact that the numbers of ana-
tomic locations for afferent cough receptors were small
the number of diseases or conditions that could stimu-
late these sites and result in chronic or persistent cough
should be equally limited. Subsequent descriptive studies
in the literature that looked at patient populations seek-
ing medical attention for a primary complaint of cough
have in fact reinforced this spectrum of conditions as
initially postulated. Only in a small proportion of
patients with chronic cough which is either due to cigar-
ette smoking or the use of an ACE inhibitor the cause
of cough could be determined [11-13]. On the other
hand, in the vast majority of the remaining patients, the
following three dominant etiologies have emerged to
explain the causes of chronic cough: upper airway
cough syndrome (UACS) due to a variety of rhinosinus
conditions, which was previously referred to as postnasal
drip syndrome (PNDS); asthma; and GERD [11-15]. In
four prospective studies from the Western World, this
triad of diagnoses was so ubiquitous that in 92 to 100%
of patients who were nonsmokers, and who were not
using an ACE inhibitor, and who had normal chest
roentgenogram findings, the presence of one, two, or
even all three of these conditions proved to be the etio-
logic explanation for chronic cough [11,15-17]. Even in
the less industrialized areas of the world (i.e. where
tuberculosis is endemic, and was an important consid-
eration as a cause of chronic cough), UACS, asthma,
nonasthmatic eosinophilic bronchitis (NAEB), and
GERD are still the most common causes seen.
It should to be clearly recognized that each of these
entities may present only as cough with no other asso-
ciated clinical findings (i.e., “silent PNDS” [now termed
UACS], “cough variant asthma, “ and “silent GERD”)
[13,18,19]. It is also important to note that the medical
history is of little value as the patient’s description of his
or her cough in terms of its character or timing, or the
presence or absence of sputum production is of little
diagnostic value [15,17]. Even in the presence of signifi-
cant hypersecretion, a nonsmoking patient who is not
receiving an ACE inhibitor and who has a normal chest
roentgenogram will usually turn out to be coughing due
to UACS, asthma, GERD, or some combination of these
diagnoses [17]. Nevertheless, the medical history is
important to rule out ACE inhibitor therapy, current as
well as a former smoking, or exposure to tuberculosis or
certain endemic fungal diseases. In addition a previous
history of cancer, tuberculosis, or AIDS, or other sys-
temic symptoms of fever, sweats, or weight loss require
consideration. An algorithm for the management of
chronic cough is shown in Figure 3.
However, it still remains important to recognize that
there are a number of other conditions, although on
average much less common, that may account for an
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example, NAEB, which is a disorder that is characterized
by cough, eosinophilic infiltration of the bronchial tree,
normal spirometry findings, a lack of bronchial hyperre-
sponsiveness, and a resolution of both cough and
eosinophilia with steroid treatment, [20-23] has been
reported to have a prevalence as an etiology of chronic
cough from as low as 13% to as high as 33% in a num-
ber of studies [16,23-26]. Until today, only a few large
studies were able to define the etiology of a chronic
Figure 3 Chronic cough algorithm for the management of cough ≥15 years of age with cough lasting > 8 weeks. ACE-I; ACE-inhibitor;
BD = Bronchodilator; LTRA = Leukotrienes receptor antagonist; PPI = Proton Pump Inhibitor. Taken from Ref [61] with permission from the
publisher.
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case of NAEB [11-14]. Nevertheless, a diagnosis of
NAEB should be considered early in the diagnostic eva-
luation as it can be reliably determined by induced spu-
tum stained for eosinophils, and by its rapid response to
(inhaled) corticosteroid therapy.
While one series [14] of patients with chronic
cough (performed in the US) described a significant
number of patients with “postinfectious” cough, other
series [11,13-16] were able to reach a high diagnostic
yield without using this category. The implication is
that most of the cases of post infectious cough had
UACS as their persistent path-physiology, transient
bronchial hyperresponsiveness, or prolonged airway
inflammation that resolved as diagnostic/therapeutic
studies were being pursued. Similarly, patients with
bronchiectasis from a variety of causes, endobron-
chial abnormalities (e.g., tumors, tuberculosis, sarcoi-
dosis, or retained sutures), isolated suppurative lower
airway infection, congestive heart failure, thyroid
disease, habitual or psychogenic cough, neuromuscu-
lar disorders, or a mediastinal mass, will occasionally
present with chronic cough as the major
manifestation.
In conclusion, the most common causes of chronic
cough are UACS due to a variety of rhinosinus condi-
tions, asthma, and GERD. Each of these diagnoses may
be present alone or in combination and may be clini-
cally silent apart from the cough itself. While there are
a number of other conditions that can result in chronic
cough, in the absence of evidence suggesting the pre-
sence of one of these other disorders, an approach
strongly focused on initially detecting the presence of
UACS, asthma, or GERD, alone or in combination, is
likely to have a far higher yield than routinely searching
for relatively uncommon or obscure diagnoses. The one
exception to this is that NAEB may be more important
than has often been recognized, is relatively easy to
diagnose with the appropriate laboratories workup, and
therefore should also be considered early in the diagnos-
tic evaluation.
Anti-Tussive Drugs
Central Antitussives
Currently available cough suppressants include centrally
acting drugs (opioids and non opioids) and peripherally
acting anti-tussives.
Opioids, such as morphine and codeine, [27,28] are
believed to inhibit cough primarily by their effect on the
cough center; opiate anti-tussives have a greater adverse
side effect profile. Because of the potential for abuse and
addiction with opioids, nonopioid anti-tussives (e.g.,
dextromethorphan) are preferred in the treatment of
acute cough. They are widely available without prescrip-
tion and thus classified as over-the-counter (OTC)
drugs. A meta-analysis of five studies with Dextrho-
methorphan and Codeine in adults concluded that these
central anti-tussives that these drugs have demonstrated
have marginally superior to placebo [29]. Table 1, 2
OTC Medicines
Self-prescribe OTC preparations which include combi-
nations of antihistamines, decongestants, cough suppres-
sants and expectorants are frequently used.
A critical analysis of a Cochrane review suggests that
the effectiveness of OTC medicines in acute cough is
weak [30]. These results, however, require a careful
interpretation because of differences in patient charac-
teristics and the quality of the studies examined.
Accordingly, some trials in the literature have generated
conflicting results which question their clinical
relevance.
This Cochrane review of the literature [30] has docu-
mented that, at least in adults, studies that compared
cough suppressants to placebo produced variable results.
Two trials have compared the expectorant guaifenesin
to placebo [31,32], but only one study showed a signifi-
cant advantage for the expectorant [33]. Another study
showed that a mucolytic can reduce the frequency and
the intensity of cough [31]. Two trials have examined
the combination of an antihistamine and a decongestant
with equivocal findings [33,34]. Three other studies
compared other combinations of drugs with placebo
and showed some benefits in reducing cough [35-37].
Table 1 Clinical Studies with Codeine
Study Sample
Size
Design Disease Results
Eccles R, et al. Lack of effect of codeine in the
treat-
ment of cough associated with acute upper
respiratory tract infection.
Journal of Clinical Pharmacy and Therapeutics
1992;17(3):175-80.
81
adults
Not reported URTI’s Codeine was no more effective
than placebo either as a single dose or in a total
daily dose of
120 mg, reported on a five-point cough severity
score (P > 0.2).
Freestone C et al. Assessment of the antitussive
efficacy of codeine in cough associated with
common cold. Journal of Pharmacy
and Pharmacology 1997;49:1045-9.
82
adults
A double-blind,
stratified, placebo-
controlled, parallel-
group,
URTI’s The results demonstrate that codeine is no more
effective than placebo in reducing cough associated
with acute URTI, as measured by CSPLs, cough
frequency or subjective symptom scores
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more effective than placebo in relieving cough
[33,38,39]. In children, cough suppressants (two studies,
one with dextromethorphan [40] and another study with
dextromethorphan plus codeine [41], antihistamines
[42,43] (two studies), antihistamine- decongestant com-
bination [44,45] (two studies) and bronchodilator-cough
suppressant combination (one study) were not more
effective than placebo [40].
Peripheral Antitussive
Regarding peripherally acting anti-tussives, levodropro-
pizine, which is an orally-administered non-opiod agent
whose peripheral anti-tussive action may result from its
modulation of sensory neuropeptide levels within the
respiratory tract [46] In clinical trials conducted in
adults, levodropropizine was compared in a double blind
studies with placebo, morclofone, cloperastine dextro-
methorphan and codeine. Table 3
The anti-tussive activity and therapeutic efficacy of the
levodropropizine were shown to be greater than placebo
and morclofone and similar to cloperastine [47]. Levo-
dropropizine was also compared to dextromethorphan
in a double blind randomized study in adults. The pur-
pose of this study was to confirm levodropropizine’s effi-
cacy and tolerability and the absence of effects on CNS.
The anti-tussive activity of levodropropizine was found
to be comparable with dextromethorphan. Subjects in
the levodropropizine group also reported less somno-
lence and nocturnal awakenings [48].
Levodropropizine was also studied in cough due to
advanced cancer [49] and interstitial lung disorders [50].
Collectively, these studies have confirmed its anti-tussive
effect and have suggested a favourable benefit/risk
profile.
Moreover, several clinical trials have demonstrated the
efficacy and tolerability of levodropropizine in paediatric
Table 2 Clinical Studies with Dextromethorphan
Study Sample
Size
Design Disease Results
Lee PCL et al. Antitussive
efficacy dextromethorphan in
cough associated with acute
upper respiratory in-
fection. Journal of Pharmacy and
Pharmacology 2000;52:1137-42.
44
adults
A double-blind, stratified, randomized and
parallel group design
URTI’s This study provides very little if any support
for clinically significant antitussive activity of a
single 30 mg dose of dextromethorphan in
patients with cough associated with URTI’s
Parvez L, et al Evaluation of
antitussive agents in man.
Pulmonary Pharmacology
1996;9(5-6):299-308.
451
adults
Review of three different studies randomized,
double blind, placebo controlled
URTI’s The results establish the sensitivity and
robustness of the cough quantization
methodology in the objective evaluation of
cough treatments
Pavesi L et al. Application and
validation of a
computerized cough acquisition
system for objective monitoring
of
acute cough: a meta-analysis.
Chest 001;120:1121-8.
710
adults
Six studies used for the meta-analysis were
randomized, double-blind, parallel-group,
single-dose, placebo-controlled studies with
a 3-h postdose cough evaluation period
URTI’s The results of a meta-analysis show that the
antitussive effect of a single dose of
dextromethorphan hydrobromide, 30 mg, has
been established.
Table 3 Clinical Studies with Levodropropizine vs Central antitussives in adults
Study Sample
Size
Design Disease Results
Allegra et al. Arneim. Forsch./
Drug Res., vol. 38 (II) 8: 1163-6,
1988.
174
adults
The studies have
been conducted as
follow:
1-2 Studies: vs
Placebo
3-4 Studies: vs
Morclofone 1%
5-6 studies:
Cloperastine drops
2%
Bronchitis - LDP antitussive action resulted in being higher than placebo and
morclofone and similar to cloperastin.
- LDP showed effective in about 80% patients: in responders the
cough frequency was reduced by 33-51%.
Catena. et al. Pulmonary
Pharmacology & Therapeutics
1997; 10: 89-96.
209
adults
Double blind
randomized vs
Dextromethorphan
Non
productive
cough
- The results bear out the effectiveness of LDP as an antitussive
comparable with dextromethorphan
- The results support a less incidence of somnolence and nightly
awakenings in the LDP’s group
Luporini G. et al Eur Respir J
1998; 12: 97-101
140
adults
Double blind
randomized vs
Dihydrocodeine
Lung
Tumor
- The antitussive effect of LDP was comparable with the reference
drug, Dihydrocodeine. LDP induced significantly less somnolence
compared to Dihydrocodeine.
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when compared with central antitussive drugs [54,55].
Table 4
In one study the efficacy and tolerability of levodro-
propizine was compared with dropropizine in the man-
agement of non-productive cough in paediatric patients.
In this study the anti-tussive effects of levodropropizine
were similar to dropropizine, but it caused less daytime
somnolence [54]. In another study in children with
bronchitis levodropropizine provided anti-tussive effi-
cacy with a more favourable risk/benefit ratio when
compared with dextromethorphan [55].
Treatment
Acute and sub acute cough
Satisfactory control of acute and sub acute cough is not
achieved in many patients resulting in substantial mor-
bidity, decrease in quality of life and loss of productivity.
Therapeutic interventions primarily aim at removing the
underlying cause of cough. Irrespective of this, the treat-
ment of cough often requires symptom related
approaches. Ideally, treatment of the underlying cause(s)
o fc o u g hw i t hs p e c i f i ct r e atments should eliminate
cough. This approach may not be successful if no cause
can be established, if treatment of the underlying disease
has a delayed onset of action or if this treatment fails.
Empiric treatment with anti-tussive agents is often
needed in particular when associated with deterioration
in the quality of life. A concept that is worth highlight-
ing is the importance of treating cough to avoid the
development of persistent cough. The potential benefits
of initiating treatment early could be in preventing the
vicious cycle of cough perpetuating cough and
decreasing the infectious spread of viruses [56]. The pre-
vention of the vicious cycle of cough could avoid many
related complications, such as fatigue, sleep deprivation,
hoarseness, musculoskeletal pain, sweating, and urinary
incontinence [56].
There may be two independent mechanisms involved.
The acute phase of the cough could be caused by a
respiratory virus or by an episode of gastroesophageal
reflux disease (GERD) through direct stimulation of
cough receptors. The inducing agent may also be
involved in the process of sensitization that may contri-
bute to a more persistent cough. The initiating event
may have disappeared, leaving a persistent cough with
or without apparent cause. This could result in an “idio-
pathic” cough, or in a cough that does not respond to
specific therapies of the associated cause(s). According
to this hypothesis, a non-specific approach to cough
suppression is always necessary [57].
While earlier studies supported their use in acute
cough more recent data suggests ineffectiveness of
codeine in the suppression of cough in the setting of
common colds [58].
The Food and Drug Administration (FDA) issued a
warning for parents and health workers against the use
of OTC products for cough and common colds in
infants and children under 2 years of age because of ser-
ious side effects and the potential danger to life that
may arise as a result of their use in children [59,60]. It
should be pointed out that the recent decision of the
members of the Consumer Healthcare Products Asso-
ciation, which represents the majority of manufacturers
of OTC medicines for cough and colds in the United
States, has been to voluntarily change the labels of these
Table 4 Clinical Studies with Levodropropizine vs Central antitussives in Children
Study Sample Size Design Disease Results
Banderali et. al J Int Med
Res 1995 May-jun;23(3):
175-83
254 children aged
between
2 and 14 yrs
Double blind
randomized
Dropropizine vs
Levodropropizine
Non-
Productive
Cough
There were statistically significant decreases in the
frequency of coughing spells and nocturnal awakenings
after both LDP and dropropizine treatments with no
statistical difference between both group. Somnolence
was twice as frequent in the dropropizine group (10.3%
vs 5.3%) and the difference is clinically relevant, though
not statistically significant.
Dong Soo Kim et al.
Diagnosis and Treatment
Vol 22. Num 9. 2002
77 children aged 2
and 3 years
Double blind
randomized LDP vs
Dextromethorphan
Bronchitis The results show the antitussive effectiveness of LDP and
point out a more favourable benefit/risk profile when
compared with dextromethorphan.
Fiocchi A et al. Ped Med
Chir 1989
70 children, age
ranged between 2
months and 14 years
Open Label Respiratory
tract
disease
- The treatment was effective on 69/70 children. No child
showed a worsening in the cough after 24 hours
treatment.
Tamburrano et al. Terapie
essenziali in clinica 1989; 3-
7
180 children aged
between 5 months
and 12 years
Open Label Respiratory
tract
disease
- The results of the present study prove that the
treatment with LDP in children is excellently tolerated
and clinically active
Banderali et al Study LPD
0191. Data on file
Unplublished
325 children aged
between 2 and 14
years
Open label Non-
productive
cough
- This study proved the a favourable therapeutic results
with limited risk of inefficacy, with the subsequent
improvement in the patient’s and parents’ quality of life,
and with remarkably limited risk of intolerance, especially
in terms of daytime somnolence.
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under 4 years of age. The American Academy of Pedia-
trics have advised against using dextromethorphan as
well as codeine for treating any type of cough in the
pediatric population, because no well-controlled scienti-
f i cs t u d i e sw e r ef o u n dt h a ts u p p o r tt h ee f f i c a c ya n d
safety of these central acting drugs as anti-tussives in
children. Indications for their use in children have not
yet been established [60]. In 2009 the Medicines and
Healthcare products Regulatory Agency (MHRA) in the
UK has discouraged the use of cough and cold remedies
containing certain agents and has indicated that they
should no longer be used in children under 6 due to an
unfavorable risk-benefits ratio. For older children (6 to
12), pharmacological treatment of cough and colds is
only recommended if basic principles of best care have
failed. The products affected by this warning also
included anti-tussives (dextromethorphan and
pholcodine).
In January 2006 the American College of Chest Physi-
cian (ACCP) published the Evidence-Based Clinical
Practice Guidelines on Diagnosis and Management of
Cough. These guidelines recommend peripheral cough
suppressant such as levodropropizine in adult patients
with cough due to acute or chronic bronchitis for the
short-term symptomatic relief of coughing [61].
In summary, acute and sub acute cough are very fre-
quent and most episodes have a benign, self-limited
course. A careful history and clinical examination is
required to identify the occasional severe underlying
condition that can present with a cough of acute or sub
acute onset.
When the therapeutic intervention aimed at removing
the underlying cause is unsuccessful, an early empiric
symptomatic treatment of acute or sub-acute cough
with anti-tussive agents is often needed in order to
improve quality of life, restore physical and social and
hopefully avoid the development of persistent cough
with deterioration in the quality of life [56,57]. As far as
the level of benefit is concerned, the effects of peripher-
ally acting anti-tussives, such as levodropropizine and
moguisteine, compare favorably with centrally-acting
drugs, based on the evidence from clinical trials and
according to the available clinical practice guidelines
[47-49,51-55,61]. Thus, peripheral anti-tussive drugs
have been recommended for the treatment of acute and
sub-acute cough, both in children and adults
Chronic cough
The objective of managing chronic or persistent cough
is to address its cause. Several prospective studies have
shown that adequate treatment of specific aetiologies of
chronic cough is effective in the vast majority of cases
[3]. However, under certain circumstances, the cause of
cough is not treatable, even if it is known (e.g.,
endobronchial lung cancer or pulmonary fibrosis). In
such situations, a non-specific (symptomatic) anti-cough
therapy for symptomatic relief seems appropriate.
Unfortunately, currently available cough suppressant
drugs are often inadequate because of their limited effi-
cacy, intolerable side effects, or both [62]. Despite evi-
dence-based medicine supporting the use of empirical
therapy in adults with chronic cough, [5,19,63] there is
no such evidence in children [64,65]. In fact, guidelines
for chronic cough from both the U.S., and Europe,
recommend the empiric use of inhaled corticosteroids
for adult patients when treating cough due to asthma,
proton pump inhibitors when the cough is associated
with GERD, and first-generation anti-histamines when it
is subsequent to an the upper airway syndrome. In chil-
dren, however, this approach is neither recommended
by the U.S. guidelines nor the Australian position paper
in light of the fact that evidence for the use of these
empirical therapies is lacking in younger age groups and
that medications cause significant side effects, especially
when used at high doses and for prolonged periods of
time [66-72]. While GERD and cough syndrome of the
upper airways might not be as common in children
where protracted bacterial bronchitis is more frequent
as well as spontaneous resolution of cough with no
apparent link between resolution and the treatment [70].
Therefore, it is not surprising that in adults, first-gen-
eration anti-histamines appear to be effective [31]
which, however, is questionable in children [32].
Health professionals often recommend the use of Self-
prescribe OTC preparations for the initial treatment of
cough, although there is little evidence for their
effectiveness.
A correct explanation of the natural history of non-
specific cough, such as cough associated with single or
multiple viral infections that resolve naturally without
pharmacological intervention will probably help patients
understand the problem and the true extent of their
cough. This should in turn lead to a reduction in the
unnecessary use of drug treatments or alleged remedies.
However, if there is an indication for symptomatic treat-
ment of a cough, e.g. in situations in which causal treat-
ment of a cough is not effective (e.g., advanced lung
cancer or interstitial lung disorders) as well as in
patients with chronic bronchitis where short-term con-
trol of symptoms is necessary should be used only drugs
which have documented clinical efficacy and/or guide-
line recommendations. Among these peripherally acting
anti-tussives, such as levodropropizine and moguisteine,
have been recommended when symptomatic relief of a
chronic or persistent cough is indicated. This recom-
mendation is based on published evidence from clinical
trials and subsequent clinical practice guidelines, where
these drugs have shown clinical efficacy with a
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ment of cough due to chronic bronchitis [28,48-50,61].
Conclusions
Cough is one of the most common symptom that
results in medical consultations [73] and is the most fre-
quent complaint of patients seeking advice from practi-
cing pulmonary physicians, accounting for up to 40% of
the practice outpatient care activity [12,74]. Coughing is
an important defensive reflex that enhances clearance of
secretions and particulate matter from the airways and
protects from aspiration of foreign materials occurring
as a consequence of aspiration or inhalation of particu-
late matter, pathogens, accumulated secretions, postna-
sal drip, inflammation, and associated inflammatory
mediators. Under normal conditions, cough plays an
important protective role in the airways and lung par-
enchyma, but in some conditions coughing may become
excessive and nonproductive, and is troublesome and
potentially harmful to the airway mucosa.
The potential benefits of treating cough early could be
in preventing the vicious cycle of cough perpetuating
cough [56]. The treatment of cough often requires
symptom related approaches. Empiric treatment with
anti-tussive agents is particularly needed when asso-
ciated with deterioration in the quality of life [57]. Avail-
able drugs for symptomatic treatment of cough include
both peripheral and central products. Recently, both the
FDA and MHRA recommended against the use of OTC
products for coughs and colds, including central anti-
tussives, in infants and young children. Furthermore, the
American Academy of Paediatrics have advised against
using dextromethorphan as well as codeine for treating
any type of cough in the paediatric population [60]. The
American College of Chest Physicians (ACCP) issued
their evidence based “Guidelines on Cough” in 2006,
which state that anti-tussive drugs related with therapy
of acute or chronic bronchitis showing the highest level
of benefit were levodropropizine and moguisteine, that
act through a peripheral mechanism, while the central
antitussive drugs such as codeine and dextromethorphan
showed a lower level of benefit.
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